The present review suggests that the upregulation of the formation of AA, a putative endogenous GPR109A agonist, is a sex-specific adaptive response aimed at preventing the development of cognitive impairment through the activation of microglial GPR109A, the inhibition of cPLA2, and the attenuation of myelin degradation. The gene discussed is PLA2G4A; the disease is Cognitive impairment.